Abbvie M14-361, A Phase I Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naive Extensive Stage Disease Small Cell Lung Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
September 1, 2015
End Date
January 25, 2017
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
September 1, 2015
End Date
January 25, 2017